EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Barriers to Hepatitis B Treatment: A Multicentre Cross‐Sectional Registry and Survey Study by the Canadian Hepatitis B Network

Hin Hin Ko iD, Jordyn Vienneau iD, Curtis L Cooper, Pam Crotty iD, Stephen E Congly iD, Mayur Brahmania iD, Alnoor Ramji iD, Erin Kelly, Angela M Crawley iD, Karen Doucette iD, Vanessa Meier-Stephenson, Mang Ma und 21 weitere

Liver International · 2026

DOI: 10.1111/liv.70835 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Hin Hin Ko und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Health Services Accessibility. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Chronic hepatitis B (CHB) remains a leading cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide, yet treatment uptake is suboptimal even in high‐resource settings. This pan‐Canadian study aimed to quantify treatment gaps within the Canadian Hepatitis B Network (CanHepB) Registry, compare characteristics of treatment‐eligible but untreated patients to those receiving therapy, and assess patient and specialist perspectives on barriers to treatment.

Methods

A cross‐sectional, retrospective analysis of 1983 adults with CHB followed in 18 Canadian hepatitis B specialty clinics between January 2018 and November 2024. Treatment eligibility was determined using the 2018 Canadian Association for the Study of the Liver guidelines. An anonymous survey captured patient‐reported barriers and perspectives ( n = 191), while a separate survey evaluated specialist perceptions ( n = 54).

Results

Among 881 untreated patients, 46.4% ( n = 409) were treatment eligible. Compared with the treatment group ( n = 1087), the treatment‐eligible but untreated patients were younger (median 47.3 vs. 54.5 years), more frequently female (54.2% vs. 39.7%), and more likely to be of Black/African/Caribbean origin (18.2% vs. 9.7%). They had a lower prevalence of cirrhosis (2.4% vs. 20.3%), HCC (0.7% vs. 9.3%), and hypertension (17.1% vs. 22.9%), but a higher prevalence of steatotic liver disease (36.4% vs. 24.6%) and dyslipidemia (14.7% vs. 10.8%). Among untreated respondents, concerns included side effects, the need for long‐term therapy, and lack of curative options. Conversely, specialists identified cost as the primary barrier and side effects as the least concerning.

Conclusion

This nationwide study reveals a significant treatment gap in CHB care, driven by demographic disparities and a mismatch between patient concerns and clinician perceptions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicAntiviral AgentsHealth Services AccessibilityHumansFemaleCross-Sectional StudiesCanadaRegistriesMiddle AgedMaleRetrospective StudiesAdultSurveys and QuestionnairesUndertreatment

Stichwörter der Autor:innen

Canadian HBV networkbarriers to treatmentchronic hepatitis B (CHB)survey

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada.
  • GastroIntestinal Research Institute, Vancouver, British Columbia, Canada.
  • Division of Gastroenterology and Hepatology, Calgary Liver Unit, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada.
  • Division of Infectious Diseases, Department of Medicine, University of Ottawa, Ontario, Canada.
  • Division of Gastroenterology, Department of Medicine, and Multi Organ Transplant Unit, Western University, London, Ontario, Canada.
  • Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

ORCID-Profile: Hin Hin Ko, Jordyn Vienneau, Pam Crotty, Stephen E Congly, Mayur Brahmania, Alnoor Ramji, Angela M Crawley, Karen Doucette, David K Wong, Jordan Feld, Nabiha Faisal, Carla Osiowy, Edward Tam, Alexander Wong, Giada Sebastiani, Tianyan Chen, Keith Tsoi, Julie Zhu, Abdel-Aziz Shaheen, Carla S Coffin

Förderung

  • Gilead Sciences

Zitieren

APA

Ko, H. H., Vienneau, J., Cooper, C. L., Crotty, P., Congly, S. E., Brahmania, M., Ramji, A., Kelly, E., Crawley, A. M., Doucette, K., Meier-Stephenson, V., Ma, M., Fung, S. K., Wong, D. K., Feld, J., Faisal, N., Kaita, K., Osiowy, C., Elkhashab, M., …, & Coffin, C. S. (2026). Barriers to Hepatitis B Treatment: A Multicentre Cross‐Sectional Registry and Survey Study by the Canadian Hepatitis B Network. Liver International. https://doi.org/10.1111/liv.70835

Vancouver

Ko HH, Vienneau J, Cooper CL, Crotty P, Congly SE, Brahmania M, et al. Barriers to Hepatitis B Treatment: A Multicentre Cross‐Sectional Registry and Survey Study by the Canadian Hepatitis B Network. Liver International. 2026. doi:10.1111/liv.70835

BibTeX
@article{Ko2026,
  author = {Ko, Hin Hin and Vienneau, Jordyn and Cooper, Curtis L and Crotty, Pam and Congly, Stephen E and Brahmania, Mayur and Ramji, Alnoor and Kelly, Erin and Crawley, Angela M and Doucette, Karen and Meier-Stephenson, Vanessa and Ma, Mang and Fung, Scott K and Wong, David K and Feld, Jordan and Faisal, Nabiha and Kaita, Kelly and Osiowy, Carla and Elkhashab, Magdy and Tam, Edward and Wong, Alexander and Bailey, Robert and Wong, Philip and Sebastiani, Giada and Chen, Tianyan and Conway, Brian and Truong, David and Tsoi, Keith and Nudo, Carmine and Zhu, Julie and Poulin, Sébastien and Shaheen, Abdel-Aziz and Coffin, Carla S},
  title = {Barriers to Hepatitis B Treatment: A Multicentre Cross‐Sectional Registry and Survey Study by the Canadian Hepatitis B Network},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70835}
}
Kostenlos starten →